Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
Oct
31
2022
CMS Heightens Oversight of TPMO Marketing Programs, Restricts TV Advertisements Sheppard, Mullin, Richter & Hampton LLP
Dec
6
2022
Don’t Let Drugs Bring You Down: The Importance of an Effective Drug Diversion Program Sheppard, Mullin, Richter & Hampton LLP
Jan
7
2020
FDA Year in Review: A Shifting Regulatory Landscape Sheppard, Mullin, Richter & Hampton LLP
Jun
6
2023
FDA Clarifies Approach to Pediatric Drug Development Sheppard, Mullin, Richter & Hampton LLP
Mar
5
2020
Nota Bene Episode 71: Shifting Regulatory Landscapes at the FDA: Cannabis, Vaping and Intelligent Medical Devices with Allison Fulton [PODCAST] Sheppard, Mullin, Richter & Hampton LLP
Mar
10
2020
Prop 65 Warnings and Acrylamide in Food – Can I Still Have My Coffee and Drink it Too? Sheppard, Mullin, Richter & Hampton LLP
Mar
16
2020
FDA Grants COVID-19 Diagnostic Emergency Use Authorizations, And Other Recent FDA Actions With to Address COVID-19 Sheppard, Mullin, Richter & Hampton LLP
Apr
1
2020
Gifting Goods & Services to the U.S. Government in the Wake of the Coronavirus Outbreak Sheppard, Mullin, Richter & Hampton LLP
Jul
17
2020
Clearing the Air: FinCEN Guidance May Help Banks Find Their Way in the Field of Hemp Financing Sheppard, Mullin, Richter & Hampton LLP
Apr
30
2024
FDA Makes Good on Its Promise to Regulate Laboratory-Developed Tests Sheppard, Mullin, Richter & Hampton LLP
Jan
12
2021
FDA’s Action Plan for Artificial Intelligence: Highlights and Insights for Developers Sheppard, Mullin, Richter & Hampton LLP
Mar
8
2021
California Legislative Update: Employment-Related Bills on the Horizon Sheppard, Mullin, Richter & Hampton LLP
Apr
26
2013
Delaware Supreme Court Affirms Preclusive Effect of Non-Delaware Dismissals and Rejects Irrebuttable Presumption That a Derivative Plaintiff Who Fails to Conduct a Section 220 Inspection Is an Inadequate Representative Sheppard, Mullin, Richter & Hampton LLP
May
2
2013
Can California Cap and Trade if Brussels Stumbles? Sheppard, Mullin, Richter & Hampton LLP
Apr
13
2018
Health Plans and Pharmacy Benefit Managers – Past and Future Sheppard, Mullin, Richter & Hampton LLP
Sep
27
2013
Details: Highlights from the August & September 2013 Federal Register Sheppard, Mullin, Richter & Hampton LLP
Nov
29
2018
CMS Issues Proposed Rule on Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses Sheppard, Mullin, Richter & Hampton LLP
Apr
26
2014
Preexisting Management Plan Not a “Mitigation Measure” for Purposes of California Environmental Quality Act (CEQA) Exemption Sheppard, Mullin, Richter & Hampton LLP
May
11
2022
Warning! FDA Issues Warning Letters for Products Containing Delta-8 THC Sheppard, Mullin, Richter & Hampton LLP
Apr
25
2019
Years in the Making: The Health Resources & Services Administration Launches a Website to Increase Pricing Transparency in the 340B Program Sheppard, Mullin, Richter & Hampton LLP
Oct
24
2014
FTC Takes Action Against Unsubstantiated Caffeine-Infused Shapewear Weight-Loss Claims Sheppard, Mullin, Richter & Hampton LLP
Jun
27
2022
Supreme Court Rules for Physicians in Blow to DOJ Sheppard, Mullin, Richter & Hampton LLP
Jul
21
2022
FDA Issues Final Guidance on Drug and Biological Instructions for Use (IFU) Sheppard, Mullin, Richter & Hampton LLP
Jun
3
2019
The U.S. Trademark Office Opens The Door to Registering Certain Cannabis Trademarks Sheppard, Mullin, Richter & Hampton LLP
Mar
4
2015
Ascertainability Saps Plaintiffs’ Energy in Dietary Supplement Class Action Sheppard, Mullin, Richter & Hampton LLP
Oct
13
2022
OIG Limits Pharmaceutical Manufacturers’ Ability to Offer Drug Cost-Sharing Subsidies Sheppard, Mullin, Richter & Hampton LLP
Feb
22
2023
CMS Releases Guidance on Implementation of Rebate Programs for Certain Medicare Part B and Part D Drugs Sheppard, Mullin, Richter & Hampton LLP
Apr
24
2023
On the Horizon: Broad Employment Protections for Marijuana Users in the District of Columbia Sheppard, Mullin, Richter & Hampton LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins